KYMR · XBRL financial data

Kymera Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KYMR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	34	73	47	79	47	39
Cost of revenue	—	—	47	79	47	39
Research and development	62	137	164	189	240	317
General and administrative	18	36	44	55	64	68
Total operating expenses	80	173	208	244	309	389
Operating income (loss)	(46)	(101)	(161)	(166)	(262)	(349)
Other income (expense)	1	0	6	19	38	38
Income tax expense (benefit)	0	0	0	—	—	0
Net income (loss)	(46)	(100)	(155)	(147)	(224)	(311)
Earnings per share, basic USD per share	(3.15)	(2.09)	(2.87)	(2.52)	(2.98)	(3.69)
Earnings per share, diluted USD per share	(3.15)	(2.09)	(2.87)	(2.52)	(2.98)	(3.69)
Weighted average shares, basic millions of shares	17	48	54	58	75	84
Weighted average shares, diluted millions of shares	17	48	54	58	75	84

Fiscal years (KYMR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	31	48	68	110	120	357
Marketable securities	265	394	339	265	368	491
Marketable securities, non-current	163	125	152	61	362	771
Accounts receivable	—	—	0	15	0	0
Prepaid and other current assets	5	9	10	12	21	23
Total current assets	302	451	419	405	510	871
Property and equipment, net	11	12	13	48	50	43
Right-of-use asset	10	9	9	53	47	42
Total assets	487	606	603	576	978	1,743
Accounts payable	4	4	4	7	6	4
Accrued liabilities	10	23	28	34	35	42
Total current liabilities	111	93	71	86	68	83
Lease liability, non-current	14	13	12	77	72	67
Total liabilities	203	146	113	181	142	163
Accumulated deficit	(129)	(229)	(384)	(531)	(755)	(1,066)
Total stockholders' equity	284	460	490	395	836	1,580
Total liabilities and equity	487	606	603	576	978	1,743
Common shares outstanding (cover page) millions of shares	45	52	55	61	65	82

Fiscal years (KYMR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(46)	(100)	(155)	(147)	(224)	(311)
Stock-based compensation	5	25	35	43	55	60
Depreciation and amortization	2	2	3	4	7	8
Net cash from operating activities	88	(129)	(153)	(103)	(195)	(233)
Purchases of property and equipment	9	2	3	34	13	1
Net cash from investing activities	(423)	(100)	21	140	(404)	(521)
Net cash from financing activities	289	250	153	4	609	991
Net change in cash	(45)	21	20	41	10	237

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Kymera Therapeutics	373	0	(78)*	85.4M	13.1 quarters	Q3 FY26 10-QSep 30, 2026
Acadia Pharmaceuticals	322	342	12*	172.8M	—	Q3 FY26 10-QSep 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	151	not reported	(160)*	799.8M	4.5 quarters	Q3 FY26 10-QSep 30, 2026
Cytokinetics	203	48	(124)*	139.3M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Vericel	133	85	not reported	51.0M	—	Q3 FY26 10-QSep 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.